SCHEMBL25031904

SCHEMBL25031904

CN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccccc4C=O)n3)cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 3/20 0.71
▸ CCNA2 P20248 3/20 0.57
▸ CDK2 P24941 3/20 0.57
▸ CDK9 P50750 3/20 0.57
▸ CDK6 Q00534 3/20 0.57
▸ CCNK O75909 2/20 0.57
▸ CCND3 P30281 2/20 0.57
▸ MAP3K7 O43318 5/20 0.55
▸ FGFR1 P11362 3/20 0.55
▸ SRC P12931 3/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ MAP2K1 Q02750 2/20 0.55
▸ PKMYT1 Q99640 2/20 0.55
▸ ALK Q9UM73 2/20 0.54
▸ EGFR P00533 2/20 0.54
▸ AXL P30530 1/20 0.53
▸ NEK2 P51955 1/20 0.53
▸ FLT3 P36888 2/20 0.52
▸ BTK Q06187 1/20 0.52
▸ PIK3CD O00329 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25032397 0.87 CCNA2 (0.75) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL2482380 0.81 SLC2A1 (0.65) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL24773089 0.78 SLC2A1 (0.63) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL29310121 0.76 SLC2A1 (0.59) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL30997614 0.76 SLC2A1 (0.59) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL29310350 0.76 SLC2A1 (0.60) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL2479934 0.76 NPC1 (0.60) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL29310349 0.76 ALK (0.60) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL30997642 0.75 SLC2A1 (0.58) SLC2A1CCNA2CDK2CDK9CDK6
SCHEMBL29310114 0.75 SLC2A1 (0.58) SLC2A1CCNA2CDK2CDK9CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134104-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM Eubulus Biotherapeutics Inc. (CN) 2023-02-15 — — EP disclosed
Send feedback